DNLI Denali Therapeutics Inc.
Price Chart
Executive Summary
Denali Therapeutics announced that Takeda has terminated their collaboration on DNL593, an investigational therapy for frontotemporal dementia caused by granulin mutations (FTD-GRN), for strategic reasons unrelated to safety or efficacy. Denali will now advance DNL593 independently, with Phase 1/2 trial results expected by the end of 2026. The company retains full rights to the program and its proprietary TransportVehicle™ platform, which enables blood-brain barrier penetration.
Actionable Insight
The termination removes a major partner but gives Denali full upside from DNL593. Investors should monitor for data readouts by end of 2026 as the next catalyst. Increased R&D burden may pressure cash, raising potential for future dilution unless new partnerships emerge.
Key Facts
- Takeda terminated its collaboration with Denali on DNL593 for strategic reasons, not due to safety or efficacy concerns.
- Denali regains full control of DNL593 and its intellectual property, allowing independent development.
- Phase 1/2 trial in FTD-GRN patients is fully enrolled (n=40), with data expected by end of 2026.
- Interim data in healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin, indicating brain delivery.
- DNL593 was generally well tolerated with no significant safety signals to date.
Financial Impact
Potential increase in R&D spend as Denali assumes full development costs; loss of Takeda funding offsets by retained economics.
Risk Factors
- Increased financial burden from funding DNL593 development alone.
- Clinical data may not translate into meaningful clinical benefit despite positive biomarker signals.
- Regulatory uncertainty for FTD-GRN therapies, with no approved treatments to benchmark against.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268105 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $21.01 awaiting T+5 | awaiting T+5 | — | $21.66 (+3.09%) |
|
May 21, 2026
22d ago
|
Press Release
| $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $21.66 (−16.20%) |
|
May 7, 2026
5w ago
|
Press Release
| $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $21.66 (+10.40%) |
|
Apr 3, 2026
10w ago
|
8-K
| $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $21.66 (+11.76%) |
|
Apr 3, 2026
10w ago
|
Press Release
| $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $21.66 (+11.76%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $22.47 $19.68 | ▼ −12.42% | ▼ −12.17% | $21.66 (−3.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access